Alpenglow Biosciences
Alpenglow Biosciences provides AI-enabled 3D tissue imaging, digital pathology, and spatial profiling solutions for researchers and clinical teams. Its platform combines light-sheet microscopy, automated volumetric data processing, and AI-powered analysis to generate quantitative insights from intact tissue samples, supporting drug development, diagnostics, and biomarker discovery. The company aims to advance biological understanding and clinical diagnostics by enabling comprehensive analysis of tissue structure and cellular relationships.
Facts
- HQ
- Seattle, Washington, USA
- Sectors
- Biotechnology Research
- Founded
- 2018
- Employees
- 32
- Total raised
- $8M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $3M · Mar 2024 SEC Form D
- Founders
- Nicholas Reder, Jonathan Liu, Adam Glaser, Larry True
Is this your organization? Claim it
GeekWire 2026 Innovation of the Year Finalists Include Alpenglow Biosciences and Pacific Northwest National Laboratory
The 2026 GeekWire Awards announced finalists for Innovation of the Year, including Alpenglow Biosciences, Pacific Northwest National Laboratory, RevealDx, Starcloud, and VerAvanti, recognized for breakthroughs in healthcare and data center technology. The awards event will be held on May 7 in Seattle, with public voting open through April 10.
Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations
Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.
People
See all 4-
Nicholas Reder Founder, Chief Executive Officer
-
Adam Glaser Founder, Co-founder
-
Jonathan Liu Founder, Co-founder
